BTCC / BTCC Square / Global Cryptocurrency /

Novo Nordisk Stock Surges as FDA Approves First Oral Weight-Loss Pill

Novo Nordisk Stock Surges as FDA Approves First Oral Weight-Loss Pill

Author:

Global Cryptocurrency

Published:

2025-12-23 10:22:02

9

2

BTCCSquare news:

Novo Nordisk shares jumped 9.5% in extended trading after the FDA granted approval for Wegovy, the first oral GLP-1 receptor agonist therapy for weight management in the U.S. The once-daily semaglutide 25 mg pill demonstrated significant efficacy in clinical trials, with participants losing an average of 16.6% body weight over 64 weeks.

The approval marks a strategic victory for Novo Nordisk, positioning it ahead of competitor Eli Lilly in the obesity treatment market. The Danish pharmaceutical giant plans a U.S. launch in early 2026, potentially revitalizing its performance after a challenging year marked by a 44% stock decline.

By:

Push to End Crypto Staking Double Taxation Gains Momentum in Washington

|Square

Get the BTCC app to start your crypto journey

Download on the App Store GEI IT ON Google Play

Get started today Scan to join our 100M+ users

Risk warning: Digital asset trading is an emerging industry with bright prospects, but it also comes with huge risks as it is a new market. The risk is especially high in leveraged trading since leverage magnifies profits and amplifies risks at the same time. Please make sure you have a thorough understanding of the industry, the leveraged trading models, and the rules of trading before opening a position. Additionally, we strongly recommend that you identify your risk tolerance and only accept the risks you are willing to take. All trading involves risks, so you must be cautious when entering the market.

The world’s longest-running cryptocurrency exchange since 2011 © 2011 - 2025 BTCC.com. All rights reserved

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.